Single nucleotide variation in the TP53 3′ untranslated region in diffuse large B-cell lymphoma treated with rituximab-CHOP: a report from the International DLBCL Rituximab-CHOP Consortium Program
Yong Li(Baylor College of Medicine), Ken H. Young(Duke Medical Center), Michael Møller(Hospital South West Jutland), Karen Dybkær(Aalborg University Hospital), Govind Bhagat(Columbia University Irving Medical Center), Maurilio Ponzoni(San Raffaele University of Rome), Dehui Zou(Chinese Academy of Medical Sciences & Peking Union Medical College), Lugui Qiu(Chinese Academy of Medical Sciences & Peking Union Medical College), Eric D. Hsi(Mayo Clinic), Ronald S. Go(Mayo Clinic), J. Han van Krieken(Radboud University Nijmegen), Zijun Y. Xu‐Monette(Duke University), Qin Huang(People's Hospital of Xinjiang Uygur Autonomous Region), Attilio Orazi(Texas Tech University), Alexandar Tzankov(University of Basel), Carlo Visco(University of Verona), Weiyun Z. Ai(City College of San Francisco), Kenneth S. Ramos(Texas A&M University System), Kristy L. Richards(University of North Carolina at Chapel Hill), Michael W. Gordon(HonorHealth), Youli Zu(Methodist Hospital), Miguel Á. Piris(Hospital Universitario Fundación Jiménez Díaz), Santiago Montes‐Moreno(Universidad de Cantabria), Andrés J.M. Ferreri(Vita-Salute San Raffaele University), Lin Wu(Materials Systems (United States)), Michael Wang(St. Joseph Health System), L. Jeffrey Medeiros(Delaware Division of Libraries), William W.L. Choi(Chinese University of Hong Kong), Jane N. Winter(Northwestern University)
Cited by 48
Related Papers
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2020|1.9k
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2013|1.7k